Publications by Odd Terje Brustugun
147 publications found
Original articles
Distribution and characteristics of malignant tumours by lung lobe
BMC Pulm Med, 24 (1), 106
DOI 10.1186/s12890-024-02918-w, PubMed 38439038
Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer
Clin Exp Med, 24 (1), 10
DOI 10.1007/s10238-023-01273-0, PubMed 38240952
Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
Eur J Cardiothorac Surg, 64 (1)
DOI 10.1093/ejcts/ezad244, PubMed 37348858
"Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer"
Diagn Pathol, 18 (1), 70
DOI 10.1186/s13000-023-01357-1, PubMed 37237384
[Hope when hopelessness beckons]
Tidsskr Nor Laegeforen, 143 (5)
DOI 10.4045/tidsskr.23.0095, PubMed 36987904
Real-World Data on EGFR and ALK Testing and TKI Usage in Norway-A Nation-Wide Population Study
Cancers (Basel), 15 (5)
DOI 10.3390/cancers15051505, PubMed 36900294
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
Transl Lung Cancer Res, 11 (10), 2064-2078
DOI 10.21037/tlcr-22-236, PubMed 36386450
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
Cancers (Basel), 14 (14)
DOI 10.3390/cancers14143430, PubMed 35884490
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Transl Lung Cancer Res, 11 (6), 953-963
DOI 10.21037/tlcr-21-995, PubMed 35832438
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
Transl Lung Cancer Res, 11 (5), 722-734
DOI 10.21037/tlcr-21-955, PubMed 35693293
Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
Front Oncol, 12, 873532
DOI 10.3389/fonc.2022.873532, PubMed 35574381
Factors affecting outcome in resected EGFR-mutated lung cancer
Acta Oncol, 61 (6), 749-756
DOI 10.1080/0284186X.2022.2066984, PubMed 35473448
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
J Clin Med, 11 (6)
DOI 10.3390/jcm11061738, PubMed 35330063
Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016
BMC Cancer, 22 (1), 220
DOI 10.1186/s12885-022-09306-9, PubMed 35227226
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
Lung Cancer, 166, 49-57
DOI 10.1016/j.lungcan.2022.02.002, PubMed 35183991
The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
Front Immunol, 12, 764596
DOI 10.3389/fimmu.2021.764596, PubMed 34868011
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study
Future Oncol, 18 (2), 205-214
DOI 10.2217/fon-2021-0746, PubMed 34784783
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
Nat Cancer, 2 (11), 1224-1242
DOI 10.1038/s43018-021-00259-9, PubMed 34870237
Factors associated with emergency-related diagnosis, time to treatment and type of treatment in 5713 lung cancer patients
Eur J Public Health, 31 (5), 967-974
DOI 10.1093/eurpub/ckab071, PubMed 34233351
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
BMC Cancer, 21 (1), 1089
DOI 10.1186/s12885-021-08811-7, PubMed 34625038
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Acta Oncol, 60 (12), 1565-1571
DOI 10.1080/0284186X.2021.1973092, PubMed 34486915
Cholangiocarcinoma treated with tumoragnostic drug
Tidsskr. Nor. Laegeforen., 141 (12), 1202-1204
Lung cancer treated with receptor tyrosine kinase inhibits abroad
Tidsskr. Nor. Laegeforen., 141 (12), 1199-1201
The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study
Cancers (Basel), 13 (17)
DOI 10.3390/cancers13174294, PubMed 34503114
Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study
Acta Oncol, 60 (10), 1250-1256
DOI 10.1080/0284186X.2021.1955971, PubMed 34313510
Phase- and gender-specific, lifetime, and future costs of cancer: A retrospective population-based registry study
Medicine (Baltimore), 100 (26), e26523
DOI 10.1097/MD.0000000000026523, PubMed 34190187
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
Lung Cancer, 157, 9-16
DOI 10.1016/j.lungcan.2021.05.017, PubMed 34051652
Societal cost of cancer in Norway -Results of taking a broader cost perspective
Health Policy, 125 (8), 1100-1107
DOI 10.1016/j.healthpol.2021.05.008, PubMed 34088521
Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
Front Oncol, 11, 674731
DOI 10.3389/fonc.2021.674731, PubMed 34109123
Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative
JTO Clin Res Rep, 2 (5), 100165
DOI 10.1016/j.jtocrr.2021.100165, PubMed 34590017
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
Lancet Oncol, 22 (3), 321-331
DOI 10.1016/S1470-2045(20)30742-7, PubMed 33662285
Factors associated with delayed treatment initiation in an unselected cohort of patients with small-cell lung cancer
Cancer Treat Res Commun, 29, 100477
DOI 10.1016/j.ctarc.2021.100477, PubMed 34700140
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
Acta Oncol, 60 (2), 149-156
DOI 10.1080/0284186X.2020.1854851, PubMed 33356733
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
DOI 10.3389/fonc.2020.590755, PubMed 33324562
Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
Clin Lung Cancer, 22 (4), e555-e562
DOI 10.1016/j.cllc.2020.09.018, PubMed 33214079
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer, 147 (10), 2957-2966
DOI 10.1002/ijc.33121, PubMed 32468587
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Acta Oncol, 59 (9), 1051-1057
DOI 10.1080/0284186X.2020.1778179, PubMed 32543258
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
Scand J Immunol, 92 (2), e12893
DOI 10.1111/sji.12893, PubMed 32433774
Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016
BMC Cancer, 20 (1), 488
DOI 10.1186/s12885-020-06979-y, PubMed 32473650
Antibody combinations for optimized staining of macrophages in human lung tumours
Scand J Immunol, 92 (1), e12889
DOI 10.1111/sji.12889, PubMed 32299134
[Cancer treatment and COVID-19]
Tidsskr Nor Laegeforen, 140 (7)
DOI 10.4045/tidsskr.20.0280, PubMed 32378865
[Lung cancer: Improved prognosis results in capacity challenges]
Tidsskr Nor Laegeforen, 140 (5)
DOI 10.4045/tidsskr.20.0014, PubMed 32238965
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Lung Cancer, 143, 27-35
DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138
Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives
Cancer Treat Res Commun, 23, 100168 (in press)
DOI 10.1016/j.ctarc.2020.100168, PubMed 32028190
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
ESMO Open, 5 (1)
DOI 10.1136/esmoopen-2019-000567, PubMed 31958290
Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP)
BMJ Open, 9 (11), e025895
DOI 10.1136/bmjopen-2018-025895, PubMed 31776134
Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
Mol Oncol, 13 (12), 2604-2615
DOI 10.1002/1878-0261.12571, PubMed 31505091
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids
Nat Commun, 10 (1), 3407
DOI 10.1038/s41467-019-11276-9, PubMed 31431620
Increase in curative treatment and survival of lung cancer in Norway 2001-2016
Eur J Epidemiol, 34 (10), 951-955
DOI 10.1007/s10654-019-00536-z, PubMed 31313073
Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway
Cancer Epidemiol, 61, 59-69
DOI 10.1016/j.canep.2019.05.004, PubMed 31153048
The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
Mol Oncol, 13 (5), 1166-1179
DOI 10.1002/1878-0261.12475, PubMed 30854794
Immune Cell Composition in Human Non-small Cell Lung Cancer
Front Immunol, 9, 3101
DOI 10.3389/fimmu.2018.03101, PubMed 30774636
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
BMC Cancer, 18 (1), 739
DOI 10.1186/s12885-018-4659-0, PubMed 30005623
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Lung Cancer, 122, 138-145
DOI 10.1016/j.lungcan.2018.06.003, PubMed 30032822
Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
Acta Oncol, 57 (9), 1225-1231
DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer
Anticancer Res, 38 (4), 2261-2269
DOI 10.21873/anticanres.12470, PubMed 29599348
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Nat Commun, 9 (1), 1048
DOI 10.1038/s41467-018-03099-x, PubMed 29535388
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
Adv Radiat Oncol, 3 (2), 130-138
DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Anticancer Res, 38 (2), 871-876
DOI 10.21873/anticanres.12296, PubMed 29374714
Cause-specific death after surgical resection for early-stage non-small-cell lung cancer
Eur J Cardiothorac Surg, 53 (1), 221-227
DOI 10.1093/ejcts/ezx274, PubMed 28950311
High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
Int J Cancer, 141 (1), 184-190
DOI 10.1002/ijc.30726, PubMed 28387924
NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
Genes Cancer, 8 (3-4), 497-504
DOI 10.18632/genesandcancer.136, PubMed 28680534
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
Lung Cancer, 103, 52-57
DOI 10.1016/j.lungcan.2016.11.018, PubMed 28024696
Real-world data on nivolumab treatment of non-small cell lung cancer
Acta Oncol, 56 (3), 438-440
DOI 10.1080/0284186X.2016.1253865, PubMed 27892773
Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
Nat Genet, 49 (1), 65-74
DOI 10.1038/ng.3722, PubMed 27869826
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
Lung Cancer, 102, 9-14
DOI 10.1016/j.lungcan.2016.10.003, PubMed 27987595
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
Radiother Oncol, 121 (1), 1-8
DOI 10.1016/j.radonc.2016.08.015, PubMed 27600155
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (11), 1349-1354
DOI 10.1080/0284186X.2016.1201216, PubMed 27549509
Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
Diagn Pathol, 11 (1), 50
DOI 10.1186/s13000-016-0504-4, PubMed 27316334
A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
Oncotarget, 7 (24), 37250-37259
DOI 10.18632/oncotarget.9363, PubMed 27191990
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Front Genet, 7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
BMC Cancer, 16, 71
DOI 10.1186/s12885-016-2104-9, PubMed 26858029
Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
F1000Res, 5, 38
DOI 10.12688/f1000research.7599.1, PubMed 27081474
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
Mol Oncol, 10 (2), 330-43
DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (5), 591-7
DOI 10.3109/0284186X.2015.1092584, PubMed 26494411
Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage
Int J Cancer, 138 (6), 1350-60
DOI 10.1002/ijc.29875, PubMed 26421593
NUT expression in primary lung tumours
Diagn Pathol, 10, 156
DOI 10.1186/s13000-015-0395-9, PubMed 26341600
EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
Acta Oncol, 55 (2), 149-55
DOI 10.3109/0284186X.2015.1062537, PubMed 26313507
Comprehensive genomic profiles of small cell lung cancer
Nature, 524 (7563), 47-53
DOI 10.1038/nature14664, PubMed 26168399
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
Clin Cancer Res, 21 (11), 2635-43
DOI 10.1158/1078-0432.CCR-14-1905, PubMed 25680376
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
Genome Biol, 16 (1), 7
DOI 10.1186/s13059-014-0558-0, PubMed 25650807
Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung
Semin Radiat Oncol, 25 (2), 87-92
DOI 10.1016/j.semradonc.2014.11.006, PubMed 25771412
Years of life lost as a measure of cancer burden on a national level
Br J Cancer, 111 (5), 1014-20
DOI 10.1038/bjc.2014.364, PubMed 24983370
[Time counts!]
Tidsskr Nor Laegeforen, 134 (9), 915
DOI 10.4045/tidsskr.14.0057, PubMed 24828708
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Nat Commun, 5, 3518
DOI 10.1038/ncomms4518, PubMed 24670920
Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
Int J Cancer, 135 (8), 1812-21
DOI 10.1002/ijc.28828, PubMed 24599520
BRAF-mutations in non-small cell lung cancer
Lung Cancer, 84 (1), 36-8
DOI 10.1016/j.lungcan.2014.01.023, PubMed 24552757
Human papilloma virus detection and typing in 334 lung cancer patients
Acta Oncol, 53 (7), 952-7
DOI 10.3109/0284186X.2013.879608, PubMed 24446743
Osteopontin is a prognostic biomarker in non-small cell lung cancer
BMC Cancer, 13, 540
DOI 10.1186/1471-2407-13-540, PubMed 24215488
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy
J Thorac Oncol, 8 (10), 1255-64
DOI 10.1097/JTO.0b013e3182a406a3, PubMed 24457236
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
DOI 10.1038/bjc.2013.450, PubMed 23942067
Rapid reduction in the incidence of cancer of unknown primary. A population-based study
Acta Oncol, 53 (1), 134-7
DOI 10.3109/0284186X.2013.783230, PubMed 23550957
Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer
PLoS One, 8 (5), e62153
DOI 10.1371/journal.pone.0062153, PubMed 23671585
Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases
J Thorac Oncol, 7 (12), 1858-1861
DOI 10.1097/JTO.0b013e318275b346, PubMed 23154557
[Stereotactic irradiation in spinal metastases]
Tidsskr Nor Laegeforen, 132 (22), 2478-9
DOI 10.4045/tidsskr.12.1108, PubMed 23338027
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Nat Genet, 44 (10), 1104-10
DOI 10.1038/ng.2396, PubMed 22941188
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations
J Thorac Oncol, 7 (9), 1471-3
DOI 10.1097/JTO.0b013e3182614a9d, PubMed 22895145
Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
BMC Cancer, 12, 333
DOI 10.1186/1471-2407-12-333, PubMed 22853000
[Mutation testing for non-small-cell lung cancer]
Tidsskr Nor Laegeforen, 132 (8), 952-5
DOI 10.4045/tidsskr.11.1017, PubMed 22562326
Characteristics and clinical validity of two immunoassays for ProGRP
Tumour Biol, 33 (4), 1105-13
DOI 10.1007/s13277-012-0351-1, PubMed 22399443
Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors
Acta Oncol, 51 (5), 603-9
DOI 10.3109/0284186X.2012.658115, PubMed 22304490
Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients
J Thorac Oncol, 7 (1), 57-63
DOI 10.1097/JTO.0b013e3182307f7e, PubMed 21900838
Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study
Acta Oncol, 50 (6), 889-96
DOI 10.3109/0284186X.2011.583266, PubMed 21767189
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
Cancer Discov, 1 (1), 78-89
DOI 10.1158/2159-8274.CD-11-0005, PubMed 22328973
EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery
J Thorac Oncol, 6 (5), 947-50
DOI 10.1097/JTO.0b013e31820db209, PubMed 21623266
Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity
Case Rep Oncol, 4 (1), 25-34
DOI 10.1159/000324113, PubMed 21526003
Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases
Thorax, 66 (4), 301-7
DOI 10.1136/thx.2010.151621, PubMed 21199818
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
Sci Transl Med, 2 (62), 62ra93
DOI 10.1126/scitranslmed.3001451, PubMed 21160078
Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
Case Rep Oncol, 3 (2), 195-201
DOI 10.1159/000317104, PubMed 20740196
The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways
PLoS One, 5 (3), e9633
DOI 10.1371/journal.pone.0009633, PubMed 20224789
[A 67-year old man with right arm paresthesias]
Tidsskr Nor Laegeforen, 129 (24), 2613-5
DOI 10.4045/tidsskr.09.0319, PubMed 20029558
Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer
Clin Chem, 54 (3), 582-9
DOI 10.1373/clinchem.2007.093195, PubMed 18171715
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
Genome Biol, 9 (5), R86
DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990
Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix
Int J Cancer, 111 (3), 358-66
DOI 10.1002/ijc.20258, PubMed 15221962
Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells
Chem Biol, 10 (7), 609-18
DOI 10.1016/s1074-5521(03)00142-x, PubMed 12890534
[Breast cancer patients' assessment of waiting time before radiotherapy]
Tidsskr Nor Laegeforen, 123 (12), 1685-6
PubMed 12821991
Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis
J Biol Chem, 277 (4), 2804-11
DOI 10.1074/jbc.M109049200, PubMed 11713251
Membrane-permeant, bioactivatable analogues of cGMP as inducers of cell death in IPC-81 leukemia cells
Bioorg Med Chem Lett, 10 (6), 571-3
DOI 10.1016/s0960-894x(00)00050-0, PubMed 10741556
Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors
Cell Death Differ, 6 (11), 1099-108
DOI 10.1038/sj.cdd.4400590, PubMed 10578179
Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2
Cell Death Differ, 5 (8), 660-8
DOI 10.1038/sj.cdd.4400399, PubMed 10200521
Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia
Leukemia, 9 (11), 1910-20
PubMed 7475283
Sensitive and rapid detection of beta-galactosidase expression in intact cells by microinjection of fluorescent substrate
Exp Cell Res, 219 (2), 372-8
DOI 10.1006/excr.1995.1241, PubMed 7641787
Cyclic adenosine monophosphate (cAMP) analogs 8-Cl- and 8-NH2-cAMP induce cell death independently of cAMP kinase-mediated inhibition of the G1/S transition in mammary carcinoma cells (MCF-7)
Endocrinology, 136 (6), 2513-20
DOI 10.1210/endo.136.6.7750473, PubMed 7750473
Review articles
Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies
J Thorac Oncol, 12 (12), 1755-1765
DOI 10.1016/j.jtho.2017.09.1956, PubMed 28962947
Implementation of lung cancer CT screening in the Nordic countries
Acta Oncol, 56 (10), 1249-1257
DOI 10.1080/0284186X.2017.1329592, PubMed 28571524
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
J Thorac Oncol, 12 (2), 194-207
DOI 10.1016/j.jtho.2016.10.003, PubMed 27729297
Stratification in advanced non-small cell lung cancer: precision medicine in practice
Expert Rev. Precis. Med. Drug Dev., 1 (3), 279-287
DOI 10.1080/23808993.2016.1176861
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
Ann Oncol, 27 (2), 225-32
DOI 10.1093/annonc/mdv560, PubMed 26578726
[Lung cancer in smokers and never-smokers]
Tidsskr Nor Laegeforen, 129 (18), 1859-62
DOI 10.4045/tidsskr.08.0652, PubMed 19844277
Other articles
[How to obtain access to medications without the Decision Forum’s approval]
Tidsskr Nor Laegeforen, 142 (2)
DOI 10.4045/tidsskr.21.0886, PubMed 35107934
[Cholangiocarcinoma treated with a tumour-agnostic drug]
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0064, PubMed 34505477
[Lung cancer treated abroad with receptor tyrosine kinase inhibitor]
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0147, PubMed 34505490
Corona vaccination of cancer patients
Tidsskr. Nor. Laegeforen., 141 (3), 211
Cancer and corona risk
Tidsskr. Nor. Laegeforen., 141 (2), 99
Cancer and coronavirus risk
Tidsskr Nor Laegeforen, 141 (2)
DOI 10.4045/tidsskr.20.1044, PubMed 33528129
[COVID-19 vaccination of cancer patients]
Tidsskr Nor Laegeforen, 141 (3)
DOI 10.4045/tidsskr.21.0026, PubMed 33624982
Cancer treatment and covid-19
Tidsskr. Nor. Laegeforen., 140 (7), 622
Lung cancer: Improved prognosis presents capacity challenges
Tidsskr. Nor. Laegeforen., 140 (5), 432-434
A NOTCH added to metabolomics
Br J Cancer, 121 (1), 3-4
DOI 10.1038/s41416-019-0463-0, PubMed 31114016
[Typical growth pattern in malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 135 (11), 1050
DOI 10.4045/tidsskr.14.0480, PubMed 26080781
[Re: In momentous development?]
Tidsskr Nor Laegeforen, 135 (5), 413-4
DOI 10.4045/tidsskr.15.0208, PubMed 25761018
[Re: Limited malignancy screening of patients with idiopathic venous thromboembolism]
Tidsskr Nor Laegeforen, 134 (8), 814-5
DOI 10.4045/tidsskr.14.0468, PubMed 24780975
Palmar bullous blistering induced by erlotinib
J Thorac Oncol, 6 (5), 954
DOI 10.1097/JTO.0b013e318211136b, PubMed 21623268
Primary osteosarcoma of the breast
Acta Oncol, 44 (7), 767-70
DOI 10.1080/02841860500254897, PubMed 16227171
Injected cytochrome c induces apoptosis
Nature, 391 (6666), 449-50
DOI 10.1038/35060, PubMed 9461210
Theses
Apoptosis: role of protein phosphorylation and cytochrome c
Department of Anatomy and Cell Biology, University of Bergen, Bergen, 1 b. (flere pag.)
BIBSYS 99060103x, ISBN 82-91424-12-8